We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Adaptive Biotechnologies (ADPT) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Adaptive Biotechnologies (ADPT - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
Adaptive Biotechnologies is a member of our Medical group, which includes 974 different companies and currently sits at #8 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Adaptive Biotechnologies is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for ADPT's full-year earnings has moved 17.6% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Our latest available data shows that ADPT has returned about 116.9% since the start of the calendar year. In comparison, Medical companies have returned an average of -1.4%. This means that Adaptive Biotechnologies is performing better than its sector in terms of year-to-date returns.
Another stock in the Medical sector, Cardinal Health (CAH - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 25.2%.
Over the past three months, Cardinal Health's consensus EPS estimate for the current year has increased 4.5%. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Adaptive Biotechnologies belongs to the Medical - Biomedical and Genetics industry, which includes 486 individual stocks and currently sits at #102 in the Zacks Industry Rank. Stocks in this group have gained about 4.3% so far this year, so ADPT is performing better this group in terms of year-to-date returns.
On the other hand, Cardinal Health belongs to the Medical - Dental Supplies industry. This 14-stock industry is currently ranked #172. The industry has moved -0.5% year to date.
Investors with an interest in Medical stocks should continue to track Adaptive Biotechnologies and Cardinal Health. These stocks will be looking to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Adaptive Biotechnologies (ADPT) Outperforming Other Medical Stocks This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Adaptive Biotechnologies (ADPT - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
Adaptive Biotechnologies is a member of our Medical group, which includes 974 different companies and currently sits at #8 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Adaptive Biotechnologies is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for ADPT's full-year earnings has moved 17.6% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Our latest available data shows that ADPT has returned about 116.9% since the start of the calendar year. In comparison, Medical companies have returned an average of -1.4%. This means that Adaptive Biotechnologies is performing better than its sector in terms of year-to-date returns.
Another stock in the Medical sector, Cardinal Health (CAH - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 25.2%.
Over the past three months, Cardinal Health's consensus EPS estimate for the current year has increased 4.5%. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Adaptive Biotechnologies belongs to the Medical - Biomedical and Genetics industry, which includes 486 individual stocks and currently sits at #102 in the Zacks Industry Rank. Stocks in this group have gained about 4.3% so far this year, so ADPT is performing better this group in terms of year-to-date returns.
On the other hand, Cardinal Health belongs to the Medical - Dental Supplies industry. This 14-stock industry is currently ranked #172. The industry has moved -0.5% year to date.
Investors with an interest in Medical stocks should continue to track Adaptive Biotechnologies and Cardinal Health. These stocks will be looking to continue their solid performance.